GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (LTS:0R0T) » Definitions » EV-to-EBITDA

Amgen (LTS:0R0T) EV-to-EBITDA : 13.52 (As of Apr. 25, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Amgen EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Amgen's enterprise value is $200,105 Mil. Amgen's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $14,801 Mil. Therefore, Amgen's EV-to-EBITDA for today is 13.52.

The historical rank and industry rank for Amgen's EV-to-EBITDA or its related term are showing as below:

LTS:0R0T' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.21   Med: 11.96   Max: 16.21
Current: 13.52

During the past 13 years, the highest EV-to-EBITDA of Amgen was 16.21. The lowest was 8.21. And the median was 11.96.

LTS:0R0T's EV-to-EBITDA is ranked better than
52.26% of 708 companies
in the Drug Manufacturers industry
Industry Median: 14.075 vs LTS:0R0T: 13.52

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), Amgen's stock price is $273.75. Amgen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $12.490. Therefore, Amgen's PE Ratio for today is 21.92.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Amgen EV-to-EBITDA Historical Data

The historical data trend for Amgen's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen EV-to-EBITDA Chart

Amgen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.95 11.95 13.36 13.96 14.04

Amgen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.96 11.18 9.86 11.44 14.04

Competitive Comparison of Amgen's EV-to-EBITDA

For the Drug Manufacturers - General subindustry, Amgen's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Amgen's EV-to-EBITDA falls into.



Amgen EV-to-EBITDA Calculation

Amgen's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=200104.888/14801
=13.52

Amgen's current Enterprise Value is $200,105 Mil.
Amgen's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $14,801 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amgen  (LTS:0R0T) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Amgen's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=273.75/12.490
=21.92

Amgen's share price for today is $273.75.
Amgen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.490.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Amgen EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Amgen's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen (LTS:0R0T) Business Description

Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen (LTS:0R0T) Headlines

No Headlines